{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"143"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"An analysis of TEAEs with an onset within the first 24 weeks of treatment was performed to examine and compare the incidence of events across an equal period for each treatment arm.Twenty-four weeks was anticipated to be the median exposure to ofatumumab.","groups":[{"description":"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.","id":"OG000","title":"Duvelisib"},{"description":"Ofatumumab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.","id":"OG001","title":"Ofatumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent to Treat","reportingStatus":"POSTED","timeFrame":"From 04 Feb 2014 till 19 June 2018","title":"Treatment-Emergent Adverse Events (TEAEs) and Changes in Safety Laboratory Values","type":"SECONDARY","unitOfMeasure":"Participants"}